Medical Condition News

RSS

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA.

29 Jun 2010

Failed ACL surgeries are more common than previously thought

Nick Van Erp, active in soccer since elementary school and lacrosse since junior high, tore the anterior cruciate ligament in his knee during a spring lacrosse game his freshman year of high school. His injury, caused by stepping into a pothole and hyper-extending his knee, required surgical repair, ending his season prematurely and the remainder of his high school sports career.

29 Jun 2010

EpiCept requests FDA priority review of Ceplene NDA for AML

EpiCept Corporation announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ceplene® (histamine dihydrochloride). EpiCept is seeking approval for Ceplene, administered concomitantly with low-dose interleukin-2 (IL-2), for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first complete remission.

29 Jun 2010

Endometriosis can affect women's work productivity

The first worldwide study of the societal impact of endometriosis has found a significant loss of work productivity among those women who suffer from the condition, a researcher told the 26th annual meeting of the European Society of Human Reproduction and Embryology today (Monday).

29 Jun 2010

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.

29 Jun 2010

Psychiatry and Pediatrics seeks volunteer families to participate in vitamin D study

Associate Professor Emeritus of Psychiatry and Pediatrics (OHSU, Portland, Oregon) is seeking roughly 50-100 volunteer families to participate in a vitamin D study. The goal of the study is to find out whether giving Vitamin D to the pregnant mother, who already has had at least one previous child with autism, can prevent the recurrence of autism in the newborn sibling.

29 Jun 2010

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced top-line results from a Phase II placebo and positive comparator-controlled, parallel-arm, double-blind, dose-response clinical trial of the novel, investigational NR2B-selective NMDA (N-methyl D-aspartate) receptor antagonist, radiprodil (RGH-896), for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPNP).

29 Jun 2010

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

Depomed, Inc. today announced that it has received a $10 million milestone payment from Abbott Products, Inc., its licensee of DM-1796, for the U.S. Food and Drug Administration's acceptance for filing of the New Drug Application (NDA) for DM-1796 for the management of postherpetic neuralgia (PHN), or pain after shingles.

29 Jun 2010

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Vietnam War-era veterans exposed to Agent Orange appear to have significantly more Graves' disease, a thyroid disorder, than veterans with no exposure, a new study by endocrinologists at the University at Buffalo has shown.

29 Jun 2010

New brain-to-computer chip technology revolutionizes neurological therapy

By stimulating certain areas of the brain, scientists can alleviate the effects of disorders such as depression or Parkinson's disease. That's the good news. But because controlling that stimulation currently lacks precision, over-stimulation is a serious concern - losing some of its therapeutic benefits for the patient over time.

29 Jun 2010

MRI study could prove useful in early detection of Alzheimer's disease

Scientists at the University of Kentucky's College of Medicine have identified changes in the brains of normal individuals at high risk for Alzheimer's disease that could prove important for early detection of the disease.

29 Jun 2010

Lead researchers develop a novel technique to deliver cancer drugs

A new way to deliver cancer drugs using gas bubbles and sound waves is to be developed at the University of Leeds. The project will enable highly toxic drugs to be delivered in small doses directly to tumours, where their toxicity can safely be put to good use.

29 Jun 2010

Cell>Point completes cancer diagnostic phase 2 trial; reports favorable trends in primary tumor imaging

Cell>Point announced today that it has closed the Phase 2 portion of its Phase 2/3 trial of 99mTc-EC-G in evaluating patients with non-small cell lung cancer.

29 Jun 2010

'Beeglue' may help deliver new treatments for fatal infections

Bees could have a key role to play in urgently-needed new treatments to fight the virulent MRSA bug, according to research led at the University of Strathclyde in Glasgow, Scotland.

29 Jun 2010

A neuro-optometric rehabilitation case report

The College of Optometrists in Vision Development (COVD) has posted its current issue of Optometry & Vision Development online and invites all to read the full-text articles free of charge.

29 Jun 2010

ITMTX treatment effective in late stages/progressive forms of MS: Study

The Multiple Sclerosis Research Center of New York (MSRCNY), together with the International Multiple Sclerosis Management Practice (IMSMP), today announced that results from its Intrathecal Methotrexate Treatment in Multiple Sclerosis study have been published in this month's issue of Journal of Neurology. This study reports on the feasibility of using intrathecal methotrexate (ITMTX) in treatment unresponsive multiple sclerosis (MS) patients with progressive forms of the disease.

28 Jun 2010

Intarcia presents ITCA 650 Phase 2 study results at 70th ADA

Intarcia Therapeutics, Inc. presented today the results of a phase 2 clinical study of ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide) for the treatment of type 2 diabetes as a late-breaker at the Annual Conference of the American Diabetes Association in Orlando, FL (June 25-29, 2010). Results of the phase 2 study demonstrated substantial reductions in HbA1c and body weight during the 12 weeks of treatment with ITCA 650 at both the 20 mcg/day and 40 mcg/day doses.

28 Jun 2010

Over 90% of U.S. adults consume twice the recommended limit for sodium intake

Less than 10 percent of U.S. adults limit their daily sodium intake to recommended levels, according to a new report, "Sodium Intake in Adults – United States, 2005-2006," published today in CDC's Morbidity and Mortality Weekly Report. The report also finds that most sodium in the American diet comes from processed grains such as pizza and cookies, and meats, including poultry and luncheon meats.

28 Jun 2010

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

Sunridge International, announced today that it has completed production and delivery of 60 PNT Units and 10,000 disposable rings to its exclusive distributor, Beijing Vision World Trading Company (BV) of China.

28 Jun 2010

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

Tarix Pharmaceuticals today announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).

28 Jun 2010

Medical Condition News

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

Failed ACL surgeries are more common than previously thought

EpiCept requests FDA priority review of Ceplene NDA for AML

Endometriosis can affect women's work productivity

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

Psychiatry and Pediatrics seeks volunteer families to participate in vitamin D study

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

New brain-to-computer chip technology revolutionizes neurological therapy

MRI study could prove useful in early detection of Alzheimer's disease

Lead researchers develop a novel technique to deliver cancer drugs

Cell>Point completes cancer diagnostic phase 2 trial; reports favorable trends in primary tumor imaging

'Beeglue' may help deliver new treatments for fatal infections

A neuro-optometric rehabilitation case report

ITMTX treatment effective in late stages/progressive forms of MS: Study

Intarcia presents ITCA 650 Phase 2 study results at 70th ADA

Over 90% of U.S. adults consume twice the recommended limit for sodium intake

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News